Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ANGIODYNAMICS INC Director's Dealing 2024

Aug 2, 2024

32939_dirs_2024-08-02_2da1721d-a9b4-49c7-b475-cc7943619126.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANGIODYNAMICS INC (ANGO)
CIK: 0001275187
Period of Report: 2024-07-17

Reporting Person: Trowbridge Stephen A (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2024-07-17 Common Stock M 11142 Acquired 177612 Direct
2024-07-17 Common Stock F 4016 $7.4 Disposed 173596 Direct
2024-07-19 Common Stock F 2585 $7.18 Disposed 171011 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-07-17 Performance Right $ M 14817 Acquired Common Stock (14817) Direct

Footnotes

F1: This acquisition of 11,142 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.

F2: The exempt disposition of 4,016 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.

F3: The exempt disposition of 2,585 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 19, 2023.

F4: On July 21, 2021, the reporting person received a target grant of 14,817 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 11,142 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.